You are here

Drugmaker AstraZeneca pushes to protect Crestor from generic competition

New York

NO more than a few hundred US children have a rare disease characterised by ultra-high levels of bad cholesterol. Yet, to the giant drugmaker AstraZeneca, this small group could be worth billions of dollars.

The company is making a bold attempt to fend off impending